Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
18 May 2017
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
The promising results from a clinical trial developed and run by investigators at Melanoma Institute Australia are being presented in Chicago at the world’s largest oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, attended by more than 30,000 delegates from around the world.
The ground-breaking Anti-PD1 Brain Collaboration (ABC) clinical trial involved advanced melanoma patients being given a combination of two different immunotherapy drugs: nivolumab (Opdivo®) and ipilimumab (Yervoy®).
Results from an early analysis of this trial show 79% of advanced melanoma patients with brain metastases treated with the combination immunotherapy were still alive at six months. 66% of those who got nivolumab alone were also alive after six months.
Typically, patients with active brain metastases survive only four to five months and never even used to be admitted to clinical trials because their prognosis was so dire.
“This is an absolute game-changer for how we treat patients with advanced melanoma which has spread to the brain. It provides new hope to the 1,800 Australians expected to die from melanoma this year,” said Professor Georgina Long, the study’s chief investigator, Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney.
“Quite simply, having brain metastases is no longer a death sentence,” she said. “We can now offer additional years of life and also the hope of ultimately beating this disease to a significant number of people.”
In February 2016, Australia approved the use of nivolumab for advanced melanoma patients as a stand-alone treatment or in combination with ipilimumab.
However, patients with brain metastases were excluded from previous clinical trials, including the ones that led to the drugs’ approval. This was what prompted Melanoma Institute Australia to develop and run the world-first ABC trial.
“I have melanoma patients with brain metastases who would not be alive today if they had not participated in this trial,” Professor Long said.
The study also examined patients who had no previous drug therapy prior to joining the trial, and those who received previous targeted drug therapy which is effective in patients with BRAF mutations in their melanoma.
It found that the combination of nivolumab and ipilimumab was more active in patients who had not received prior targeted BRAF-directed drug therapy.
Under the current Pharmaceutical Benefits Scheme (PBS) in Australia, doctors are restricted in the order in which they can prescribe the targeted BRAF-directed drug therapies and immunotherapy as treatments for melanoma. The restrictions make it very difficult to give immunotherapy first to patients who have the BRAF mutation in their melanoma (approximately 40% of all melanoma patients).
However, this new research strongly suggests that immunotherapy should be the first-line treatment in suitable patients, in particular, those with brain metastases.
Young dad, Leigh Miller (pictured here), is just one of the patients on the ABC Trial who has had a remarkable turnaround.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Charity Rugby Match - Cronulla Sharks vs West Tigers
Join us on Saturday, 17 June for the Cronulla Sharks vs West Tigers charity game, to raise funds and awareness for Melanoma Institute Australia.
Melanoma March 2017 wraps up!
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
Whole genome sequencing finds unexpected genomic landscape in melanoma
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
Shining a light on melanomas that aren't caused by the sun
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
New research which more accurately predicts survival for melanoma patients
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
Celebrating 60 Years of melanoma research to save lives
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Celebrating our research achievements
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
Global Melanoma Research Report - April
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.
The people behind the Professors
Professor’s Long and Scolyer are well known in the academic community and beloved by their patients. But we wanted to get to know our new Conjoint Medical Directors a little more and hear their plans on making an impact on melanoma.
Wyong Rugby Leagues kicks goal to help end melanoma
Wyong Rugby League Club Group has joined forces with Melanoma Institute Australia to help end melanoma for future generations.
Melanoma research reaches a milestone
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
Contributing to the promise of Surgical Oncology
MIA's researchers and clinicians are in Seattle, USA, today sharing their research findings at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium.
Introducing Melanoma Institute Australia's Conjoint Medical Directors
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.
A day in the life of... Georgia Cairns CNC
Meet Georgia, our Clinica Nurse Consultant who provides vital care and education for patients throughout their treatment.
The real tragedy on Married At First Sight that Australia should be talking about....
Australia, we need to talk. This week’s dramatic episodes of Married At First Sight have highlighted a tragedy which is ripping Australian families apart. Yet no one is talking about it.
Melanoma Institute Australia celebrates International Women's Day
To celebrate International Women's Day 2017, MIA shares how some of the women who inspire the way we work every day, are showing their commitment to accelerate gender parity.
New Chairman of the Board for Melanoma Institute Australia
We welcome Mr Grant King to the position of Chairman of the Board of Melanoma Institute Australia, following the retirement of Mr Reg Richardson AM who led the organisation for 10 years.
MIA student honoured with NSW National Council of Women Australia Day Award
Congratulations to PhD Student, Tuba Nur Gide who was awarded a NSW National Council of Women Australia Day Award for her PhD research work.